Education · Liver Transplant & Cancer

Liver Transplantation & Cancer

How hepatocellular carcinoma (HCC) and other primary liver cancers interact with transplant eligibility, MELD exceptions, oncologic criteria, and long-term outcomes after liver transplantation.^[1][2]

Gross specimen of hepatocellular carcinoma in a cirrhotic liver

Hepatocellular carcinoma most often develops on a background of cirrhosis and chronic liver disease.

Liver transplantation can cure both the tumor and the underlying cirrhosis in carefully selected patients with early-stage HCC. Selection depends on tumor size and number, imaging features, and biologic behavior such as alpha-fetoprotein (AFP) levels.^[1][3]

This page explains:

When cancer patients are considered for liver transplant
Milan criteria and related oncologic frameworks
Standardized MELD exception policy for HCC
Recurrence risk and follow-up after transplant
The role of living donation in HCC

Overview: Cancer & Liver Transplantation

Primary liver cancer is most commonly hepatocellular carcinoma, usually arising in a cirrhotic liver. For selected patients with early-stage HCC, liver transplantation offers a chance at cure by removing both the tumor and the diseased liver that allowed cancer to grow.^[1][2][4]

Modern guidelines emphasize accurate staging, imaging diagnosis, tumor biology, and response to locoregional therapy when determining transplant eligibility, with the goal of keeping recurrence risk low while preserving excellent long-term survival.^[1][2]

Liver transplant is typically reserved for early HCC with controlled tumor burden and good functional status, where the benefits of surgery and lifelong immunosuppression clearly outweigh the risks.

HCC & Eligibility for Transplant Listing

Patients with cirrhosis and small HCC lesions may be considered for liver transplantation when tumors meet established size and number criteria, and when there is no macrovascular invasion or extrahepatic spread on imaging.^[1][2][3]

Diagnosis is usually based on characteristic CT or MRI patterns (arterial enhancement and washout).
AFP and other markers help reflect tumor biology and risk of recurrence.
Locoregional therapies (ablation, TACE, Y-90) may be used as bridging or downstaging tools.
Candidates must also satisfy standard medical and psychosocial transplant criteria.

OPTN/UNOS policy recognizes HCC as a special indication and provides standardized MELD exception pathways for eligible patients to balance urgency and fairness in liver allocation.^[4][5]

Milan Criteria & Other Oncologic Frameworks

The Milan criteria remain the benchmark for selecting HCC patients for liver transplantation and are used worldwide because they provide excellent survival and low recurrence rates.^[3][6]

Single HCC ≤ 5 cm, or
Up to three HCC lesions, each ≤ 3 cm
No macrovascular invasion
No extrahepatic disease

Expanded criteria (such as UCSF or “up-to-seven”) broaden eligibility in some centers while still aiming to preserve low recurrence risk and favorable outcomes.^[6][7]

When Milan criteria are respected, 5-year post-transplant survival can approach 70–80%, similar to outcomes for non-malignant indications.^[3][8]

MELD Exception Policy for HCC

Many HCC patients have relatively preserved synthetic liver function, so their laboratory MELD scores do not fully reflect cancer-related urgency. In the U.S., standardized MELD exception points are granted for eligible HCC cases under national policy.^[4][5][9]

Exception eligibility requires tumors within defined size/number limits and acceptable AFP levels.
Cross-sectional imaging is updated about every 3 months to ensure disease remains within criteria.
Non-standard or complex cases are reviewed by the National Liver Review Board.
Recent policy revisions aim to reduce excessive advantage and geographic disparities.

MELD exceptions for HCC are intended to recognize tumor-related risk while maintaining fairness with non-HCC candidates on the waiting list.^[4][5][9]

Post-Transplant Recurrence & Follow-Up

The main oncologic concern after liver transplantation for HCC is tumor recurrence, which most often appears in the liver graft, lungs, or bone. Recurrence typically occurs within the first 2–3 years after transplant.^[2][8]

Higher risk is associated with large tumors, vascular invasion, and very elevated AFP.
Downstaging and response to locoregional therapy are important prognostic indicators.
Post-transplant surveillance uses periodic CT/MRI and AFP monitoring.
Immunosuppression regimens may be adjusted to reduce cancer-promoting effects.

With careful selection and modern surveillance, long-term survival after transplant for HCC can closely resemble outcomes for patients transplanted for non-malignant disease.^[2][7]

Living Donor Liver Transplantation in HCC

Living donor liver transplantation (LDLT) can shorten waiting time for eligible HCC patients and reduce the risk that tumors will progress beyond transplant criteria while they wait.^[7][8]

Allows a planned operation rather than waiting indefinitely for a deceased donor liver.
May decrease waitlist dropout due to tumor growth or decompensation.
Oncologic outcomes can be comparable to deceased donor liver transplant when criteria are respected.
Requires a thorough evaluation of both donor and recipient for safety and ethical considerations.

Illustration of a left liver transplant with vascular reconstruction

Illustration of left liver transplantation, highlighting the vascular anatomy and reconstruction required in partial liver grafts.

LDLT for HCC can be a powerful strategy to avoid tumor progression while maintaining strict oncologic selection criteria and provides an additional option when deceased donor organs are scarce.^[7][8]

References

← Return to Pre-Transplant Guide